Navigation Links
Nature's Bioceuticals Tears Into the Multi-Billion Dollar Chronic Kidney Disease Market
Date:11/1/2011

CAPE CORAL, Fla., Nov. 1, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it will purchase the exclusive rights to a formula that was developed to restore proper kidney function in people with chronic kidney disease (CKD).

Chronic kidney disease is a growing health problem in the United States. A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. Thus, one in six individuals has kidney disease. By disease stage, the prevalence is as follows: stage 1, 3.1%; stage 2, 4.1%; stage 3, 7.6%; stage 4; and 5, 0.5%. There are over 500,000 persons on dialysis or who have received kidney transplants.  The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease.

Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion. The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion. The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.

Robert deZanger, CEO of Natures Bioceuticals stated "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product. Obviously, this product should create substantial revenues for the company and we are excited about the possibilities. Capturing just 0.5% of the market could produce revenues in excess of $100,000,000.00 and with the correct marketing program we believe it could be possible to capture a greater percent of the market within the first few years.  Upon closing of the purchase we intend to file the patent documents and then immediately proceed with formal clinical trials to document the amazing results obtained to this point."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com


'/>"/>
SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
2. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
3. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
4. Aprima Customers Earn "Meaningful Dollars"
5. AquaStar Holdings, Inc.s Subsidiary Signs Multi-Million Dollar Venture Accelerator Agreement To Develop Portable Healthcare Diagnostic Technology
6. Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize
7. Med Gen Inks Multi-Million Dollar Funding Deal
8. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
9. Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment
10. Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes
11. ActiViews Raised $5M Dollars, in a Round led by 7 Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/5/2017)... , Sept. 5, 2017  Xyntek Inc. has announced another milestone in ... new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West ... ... customer engagements regionally. ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... The ... “Humans With Vaginas.” The goal is to ignite conversation via social media and ... products. The brand has declared September “Humans with Vaginas” month, releasing a video ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... Houston, ... entire team took Friday, September 8, and Monday, September 11, off work and rolled ... Second Baptist Church before heading to local homes to start the process of rebuilding. ...
(Date:9/20/2017)... ... 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning ... author, Jeanine Liston, a busy mother of five who used her time waiting for children ... book for over twenty years. It was a way to give some meaning to ...
Breaking Medicine News(10 mins):